Translumina Yukon -Model Choice PC -Sirolimus Eluting Coronary Stent System
The Translumina Yukon Choice PC drug-eluting stent, coated with Rapamycin (Sirolimus) and the biodegradable component polylactide (PLA), has an excellent history of pre-clinical and long-term clinical results.
In two independent trials ISARTEST 3 and ISAR-TEST 4 the Yukon Choice PC showed improved long-term performance compared to 1st. Generation DES over a time period of 10 years clinical follow-up in the randomized controlled clinical trial.
Clinical data, published by G.Stefanini et al, show the excellent long-term outcome of the Yukon Choice PC in a meta- analysis, comparing the clinical outcome after 4 years in more than 4000 patients with the Cypher stent. This analysis shows for the first time that the definite Very Late Stent Thrombosis (VLST) can be reduced statistically significant by using the bio- degra dable PLA polymer coating technology of the Yukon Choice PC.
An additional sub-group analysis shows also benefit in difficult patient groups like diabetics and patients with acute myocardial infarkt.
Due to this excellent clinical outcome the Yukon Choice PC is recommended by the latest ESC guidelines for myocardial revascularization.
Better Endothelialisation & Superior Strut Coverage
- Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue
- No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis
- Crossing profile (0 2,5 mm) : 0.94 mm (0 2.5 mm)
- Strut thickness : 90 Mm (SV). 95 urn (MV)
- Metallic surface area : 13 - 20%
- No foreshortening
- Balloon marker material : Platinum / Iridium
- Entry profile : 0.016" /0.41mm
- Proximal shaft diameter : 1.9 F
- Distal shaft diameter : 2.7 F
- Recommended guide wire : 0,014"
- Guiding Catheter : min. 5 F
Unique stent surface
The micro-porous stent surface, called PEARL Surface, favours better endothelialisation, which is essential for avoiding thrombosis and restenosis.
Stent design
- homogeneous expansion
- increased radial force
- good side branch access
Low stent profile
- flexible and deliverable
- strut thickness of 87µm in the range of CoCr platforms